Outcome summaries · provisional pilot

CBN and wake after sleep onset in insomnia

Selected human studies, their reported effects and the limits of this source set.

Provisional · source checks 2026-11-08 UTC · scientific editorial review pending

The question and its scope

Population
Adults with physician-diagnosed insomnia disorder in the selected acute crossover trial
Studied preparation
Defined CBN oral preparations and matched placebo
Route
oral
Primary outcome
Polysomnographic wake-after-sleep-onset minutes; secondary sleep measures kept separate
Study scope
Single-night arms in one three-arm crossover cohort; repeated observations do not multiply participant or trial counts

Reported finding · selected human evidence

Neither CBN contrast clearly improved the primary objective wake-after-sleep-onset outcome. Findings on other sleep measures do not establish primary-outcome success.

One small, single-night crossover cohort; sustained benefit and long-term safety remain unresolved.

1 distinct randomized cohort in this source set. Mixed-cannabinoid medicinal-cannabis trial is a different preparation and not evidence for CBN alone.

Reported effects and harms

Estimates retain their original comparator, units and 95% confidence interval (CI). Different measures are not pooled. Study regimens identify the research; they are not treatment instructions.

Human · primary randomized study

Lavender et al. (2026)

Acute CBN crossover cohort · NCT05344170 ↗

20 adults received all three conditions and were analyzed. Repeated observations are not 60 different participants.

Both primary confidence intervals include zero.

ContrastMeasureEstimate95% CI
30 mg CBN versus placeboWake-after-sleep-onset difference−4.0 minutes−15.9 to +7.9 minutes
300 mg CBN versus placeboWake-after-sleep-onset difference−6.3 minutes−18.2 to +5.5 minutes
Harms reported
247 mild-to-moderate events were recorded across conditions. This is an event total, not a participant count; no formal adverse-event hypothesis test was performed.
Interpretation limits
Small selected sample, one night per condition and many outcomes; no formal sample-size calculation.
Source depth
Primary full text: Methods 2.6–2.9, Results and adverse events.

Context kept separate

These records do not add independent primary human trials to the count above.

Human context

Animal context

No animal context selected in this pilot source set.

Laboratory context

No laboratory context selected in this pilot source set.

Source checks and notices

The selected PubMed records were checked 2026-11-08 UTC. No other notice signals were returned for these records at that check; missing metadata signals do not prove that no notice exists. This monitor checks citation relations, not every full-text change, and never rewrites a finding automatically.

Read this question’s selection record and omitted-source limits →